デフォルト表紙
市場調査レポート
商品コード
1410882

コレステロール検査市場:市場規模(セグメント別)、シェア、規制、償還、予測(~2033年)

Cholesterol Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
コレステロール検査市場:市場規模(セグメント別)、シェア、規制、償還、予測(~2033年)
出版日: 2023年12月07日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コレステロール検査は、血液中に存在するコレステロール値の上昇を確認するために実施されます。血中コレステロール値の上昇は、心臓発作、脳卒中、末梢動脈疾患のリスクを高める可能性があります。高血圧の有病率は最大の要因の一つです。

血中コレステロールの測定には、高比重リポ蛋白(HDL)、低比重リポ蛋白(LDL)、総コレステロールなどいくつかのパラメータがあります。HDLは「善玉コレステロール」のマーカーであり、LDLは「悪玉コレステロール」のマーカーとして知られています。総コレステロールは、「善玉」と「悪玉」の両方のコレステロールを含む血液中のコレステロールの全体量です。

コレステロール検査モデルは、高比重リポ蛋白(HDL)コレステロール検査、低比重リポ蛋白(LDL)コレステロール検査、総コレステロール検査、マルチパラメータ・コレステロール検査にセグメント化されます。

当レポートは、世界のコレステロール検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されているコレステロール検査と競合情勢

  • 主要な業界動向の洞察
  • コレステロール検査のセグメント別総市場収益と2015年~2033年の市場展望
  • 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

  • コレステロール検査市場のSWOT分析
  • コレステロール検査市場に関する競合力学の洞察と動向
  • 国別の医療制度の概要
  • 国別の償還政策
  • 国別の医療技術に関する規制の状況
図表

List of Tables

Not Applicable

List of Figures

Not Applicable

目次

Abstract

Cholesterol Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Cholesterol Tests market for the year 2020 and beyond. Cholesterol test is performed to identify elevated levels of cholesterol present in the blood. Elevated levels of cholesterol in the blood may increase the risk of heart attack, stroke, and peripheral artery disease. The prevalence of hypertension is one of the largest drivers.

There are a few parameters for the determination of cholesterol in the blood, such as high-density lipoproteins (HDL), low-density lipoproteins (LDL), and total cholesterol. HDL is a marker of "good cholesterol", whereas LDL is known as a marker of "bad cholesterol"; total cholesterol is the overall amount of cholesterol in the blood, including both "good" and "bad" cholesterols.

Cholesterol Tests model is segmented into High-Density Lipoprotein (HDL) Cholesterol Lab Tests, Low-Density Lipoprotein (LDL) Cholesterol Test, Total Cholesterol Test and Multi-parameter Cholesterol Test.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Cholesterol Tests and evolving competitive landscape:

  • Insightful review of the key industry trends.
  • Annualized total Cholesterol Tests market revenue by segment and market outlooks from 2015-2033.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Cholesterol Tests market.
  • Competitive dynamics insights and trends provided for Cholesterol Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Danaher Corp, Helena Laboratories Corp, QuidelOrtho Corp, F. Hoffmann-La Roche Ltd, Siemens AG, Thermo Fisher Scientific Inc, Randox Laboratories Ltd, Sekisui Chemical Ltd, Alfa Wassermann Inc, Merck KGaA, Sinocare Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Cholesterol Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Cholesterol Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Cholesterol Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cholesterol Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Cholesterol Tests market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable